Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study

AIMS: To assess the efficacy, insulin dose, safety and immunogenicity when people with type 1 diabetes mellitus switched between MYL‐1501D and reference insulin glargine (Lantus®; Sanofi‐Aventis US LLC, Bridgewater, New Jersey). MATERIALS AND METHODS: Eligible participants from INSTRIDE 1 who comple...

Descripción completa

Detalles Bibliográficos
Autores principales: Blevins, Thomas C., Barve, Abhijit, Raiter, Yaron, Aubonnet, Patrick, Athalye, Sandeep, Sun, Bin, Muniz, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065063/
https://www.ncbi.nlm.nih.gov/pubmed/31691472
http://dx.doi.org/10.1111/dom.13904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065063/
https://www.ncbi.nlm.nih.gov/pubmed/31691472
http://dx.doi.org/10.1111/dom.13904

Ejemplares similares